The BCL2L12 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population engineered to disrupt BCL2L12 gene function in the near-haploid HAP1 cell line. This loss-of-function model is designed for investigating the role of BCL2L12 in intrinsic apoptosis and its implications in leukemia biology and drug resistance. The polyclonal format ensures genetic diversity, making it suitable for pooled screens and studies where heterogeneous gene disruption is advantageous.
HAP1 is a near-haploid human cell line derived from the male KBM-7 chronic myeloid leukemia (CML) line. Its haploid karyotype allows clean loss-of-function phenotypes with single-allele disruption, facilitating unambiguous genotype?Cphenotype correlations. The cells grow in suspension and retain BCR-ABL dependency, providing a physiologically relevant context for studying CML and other hematological malignancies.
BCL2L12 is a pro-apoptotic BH3-only protein regulated by TP53 and activated by DNA damage. It promotes mitochondrial outer membrane permeabilization by neutralizing anti-apoptotic BCL-2 and BCL-XL, thereby enabling BAX/BAK oligomerization, cytochrome c release, and activation of the caspase cascade (caspase-9 and -3). These interactions place BCL2L12 as a key mediator between upstream apoptotic signals and mitochondrial execution.
In the leukemic HAP1 background, BCL2L12 knockout facilitates the study of apoptosis resistance common in CML. The near-haploid nature ensures complete loss of pro-apoptotic function, making cells more reliant on anti-apoptotic BCL-2 proteins for survival. This model is valuable for testing chemotherapeutics and BCL-2 inhibitors, as BCL2L12 deficiency can mimic drug-resistant states and reveal synthetic lethal vulnerabilities.
Applications include Western blotting to assess BCL2L12 loss and downstream caspase activation, Annexin V flow cytometry for quantifying apoptosis, caspase-3/7 activity assays, and co-immunoprecipitation to study BCL-2 family interactions. Drug sensitivity profiling can be performed to evaluate responses to standard-of-care agents or targeted therapies. The polyclonal format also supports pooled CRISPR screens and genetic interaction studies. For inquiries, please contact Ascent Research.
